Does Jardiance Cause Weight Loss? What the FDA Label Actually Says

Quick answer

As of September 2026, the FDA-approved label for Jardiance (empagliflozin) lists 4 indications, and weight management is not one of them. Jardiance is approved to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, to slow kidney decline and reduce related risks in adults with chronic kidney disease, to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to improve glycemic control in type 2 diabetes alongside diet and exercise. Body weight appears in the label only as a measurement reported in its diabetes trials. Whether Jardiance is appropriate for anyone, for any reason, is a decision for a licensed physician.

Does Jardiance cause weight loss?

Searches for Jardiance weight loss usually come down to two questions, and the label answers both.

First, Jardiance is not approved for weight loss. The indications section of the prescribing information names heart failure, chronic kidney disease, cardiovascular risk reduction in type 2 diabetes, and glycemic control. It does not name obesity, overweight, or weight management. The Medication Guide, the patient-facing part of the same label, does not mention weight at all.

Second, the label's clinical studies section, which describes the trials run for the glycemic-control indication, reports body weight as one of the measurements taken alongside blood sugar. In those type 2 diabetes trials, the label describes reductions in HbA1c, fasting plasma glucose, and body weight compared with placebo. That is a qualitative statement about what was measured in people with diabetes who were enrolled to study blood sugar. It is not an approved use, it was not studied as a weight-management treatment in the label, and it says nothing about what would happen in a person without diabetes.

So if the question is "does the label say Jardiance is a weight loss drug?", the answer is no. If the question is "does the label mention body weight?", the answer is yes, as a trial measurement, and nothing more.

How does Jardiance work?

Jardiance belongs to a class called SGLT2 inhibitors. The label's mechanism section explains that SGLT2 is the main transporter that pulls glucose out of the kidney's filtrate and returns it to the blood. By blocking SGLT2, empagliflozin reduces how much filtered glucose the kidney reabsorbs, lowers the threshold at which glucose spills into urine, and so increases the amount of glucose leaving the body in urine. The label adds that the drug also reduces sodium reabsorption, which may influence pressure inside the kidney, the workload of the heart, and sympathetic nervous activity. The label presents these as possible effects and does not state them as the basis for any indication. Farxiga (dapagliflozin) is another drug in the same class, and what Farxiga costs covers its price and its own label the same way.

That mechanism is very different from how GLP-1 medications work, which act on appetite and digestion through hormone receptors. Jardiance is not a GLP-1 medication and does not belong in a conversation about GLP-1 alternatives.

What is Jardiance actually approved for?

Reading straight from the indications section, as of September 2026:

1. To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
2. To reduce the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
3. To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
4. As an adjunct to diet and exercise to improve glycemic control in adults and children aged ten and older with type 2 diabetes mellitus.

The same section carries limitations of use. The label says Jardiance is not recommended for glycemic control in type 1 diabetes because it may increase the risk of diabetic ketoacidosis. It is also not recommended for glycemic control when kidney function is below a threshold the label specifies, and not recommended for chronic kidney disease in people with polycystic kidney disease or in people who need, or recently had, intravenous immunosuppressive therapy or high-dose prednisone for kidney disease, because the label states it is not expected to be effective in those groups.

If you want to learn how to find these sections yourself, our guide on how to read a prescription label walks through where indications, warnings, and contraindications live.

What does "off-label" mean here?

FDA has a plain-language patient page on unapproved uses of approved drugs. It explains that before approval a company must demonstrate to FDA that a drug's benefits outweigh its risks for its intended uses, and that once a drug is approved, healthcare providers generally may prescribe it for an unapproved use when they judge that it is medically appropriate for their patient. FDA calls this off-label use and gives examples such as using a drug for a condition it was not approved to treat. Naltrexone used for weight sits in that same category, because what naltrexone is approved to treat is alcohol dependence and opioid blockade, not weight.

Two things follow. Off-label prescribing is legal and common, and it is a clinical judgment that belongs to a licensed physician who has examined the patient. Nothing on this page, and nothing in a search result, is a substitute for that judgment. This article does not recommend Jardiance for weight loss and does not explain how to obtain it for that purpose. It explains what the label says so that a conversation with a physician starts from facts.

We apply the same discipline to other medicines people ask about, such as Trulicity and topiramate: read the label, name what it is approved for, and leave the decision where it belongs. Bupropion raises the same question, and what the Wellbutrin XL label says about weight answers it the same way.

What are the warnings and precautions on the Jardiance label?

The warnings section is where the label earns its length. In plain words, these are the categories it names.

Ketoacidosis. The label says Jardiance can cause ketoacidosis, a life-threatening buildup of acid in the blood, and that fatal cases have occurred in people with type 2 diabetes as well as type 1. Blood glucose at presentation may be lower than is typically expected for diabetic ketoacidosis. The list of precipitating conditions is worth reading closely if weight is on your mind: it includes reduced caloric intake, a ketogenic diet, surgery, volume depletion, acute febrile illness, and alcohol abuse. Symptoms include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. The label instructs patients to stop the drug and seek medical attention immediately if those symptoms occur.

Volume depletion. Because the drug pulls glucose and sodium into the urine, it can reduce fluid volume in the blood vessels. The label describes symptomatic low blood pressure and acute changes in kidney markers, and notes postmarketing reports of acute kidney injury. Older adults, people with reduced kidney function, and people on loop diuretics are named as higher risk.

Genitourinary infections. The label links the drug's increased urinary glucose excretion to a higher risk of genitourinary infections. The label lists urinary tract infections and genital yeast infections in both sexes, and serious infections including urosepsis, pyelonephritis, and necrotizing fasciitis of the perineum, also called Fournier's gangrene, a rare, life-threatening infection that requires urgent surgery. The label says to seek care right away for pain, tenderness, redness, or swelling in the genital or perineal area with fever or malaise.

Hypoglycemia. The label says insulin and insulin secretagogues are known to cause hypoglycemia, that the risk may be increased when Jardiance is combined with insulin or an insulin secretagogue such as a sulfonylurea, and that in pediatric patients aged ten and older the risk was higher with Jardiance regardless of insulin use.

Lower limb amputation. The label reports an imbalance in amputations seen with SGLT2 inhibitors in some studies, names peripheral artery disease and diabetic foot infection as the most common precipitating events, and asks prescribers to monitor for foot sores and infections.

Hypersensitivity reactions. Serious reactions including angioedema have been reported after approval. The label says to stop the drug and treat promptly.

Who should not take Jardiance?

The contraindications section is short. Jardiance is contraindicated in anyone with hypersensitivity to empagliflozin or any of the excipients in the tablet, and the label notes that reactions such as angioedema have occurred. The limitations of use described earlier, especially the type 1 diabetes limitation, are not formal contraindications but carry the same practical weight for the physician deciding whether to prescribe.

What Jardiance side effects does the label list?

Without attaching numbers, the label's adverse reactions section names urinary tract infection, female and male genital yeast infections, upper respiratory tract infection, increased urination, dyslipidemia, joint pain, and nausea among reactions reported in the diabetes trials. Its postmarketing section adds constipation, Fournier's gangrene, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, and skin reactions such as rash and hives. The label is careful to say that postmarketing reports come from a population of uncertain size, so their frequency cannot be reliably estimated. We report them the same way.

Where do FDA-approved weight-management medicines fit?

If weight is the actual goal, the relevant comparison is not Jardiance against diet. It is Jardiance's label against the labels of medicines that carry a weight-management indication. As of September 2026, the Zepbound label states it is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight and at least one weight-related condition. The Saxenda label carries the same kind of language. The Wegovy label is likewise written for use in combination with a reduced calorie diet and increased physical activity.

That is what an approved weight-management indication looks like on paper: the word "weight" is in the indication itself, with eligibility criteria and the diet-and-activity context spelled out. Jardiance's label has none of that. For an overview of the products that do, see our guide to Wegovy alternatives. Whether any of these medicines is right for a particular person, including whether a compounded version is even a consideration, is a physician's call. Compounded medications are not FDA-approved as final products.

Questions to bring to your physician

If you take Jardiance, or a physician has suggested it, these questions come straight from the label and keep the conversation grounded.

• Which of the four approved indications applies to me, and if none does, why are you considering it?
• Do I have any of the ketoacidosis risk factors the label names, and should I be monitoring ketones?
• I am planning to reduce my calories or try a low-carbohydrate diet. Does the label's warning about reduced caloric intake and ketogenic diets change anything?
• Am I on insulin, a sulfonylurea, or a loop diuretic, and does that change my risk of low blood sugar or dehydration?
• What signs of a genitourinary infection should make me call you the same day?
• How is my kidney function, and how often will you check it?
• If my goal is weight management, which medicines carry that indication on their label, and am I a candidate for any of them?

If you have questions about how physician review works in telehealth generally, our help center explains the process without any claims about outcomes.

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Jardiance is a registered trademark of Boehringer Ingelheim; Wegovy and Saxenda are trademarks of Novo Nordisk; Zepbound is a trademark of Eli Lilly and Company. This page is not affiliated with any of them.